Our case emphasizes the importance of screening psoriatic patients for fungal infections before and after the treatment with anti-IL-17 biologics in order to exclude a concomitant undiagnosed superficial mycosis or the risk of its exacerbation. Here, IL17A is linked to superficial mycosis.